2 completed, 1 recruiting. 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Dara SC: new trials by email Literature Review of Dara SC trials Research Report on Dara SC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid dFLC Response Predict CHR in AL Amyloidosis Dara IV, Bortezomib (drug), Dexamethasone - Systemic AL Amyloidosis | Recruiting | Peking University People's Hospital | 50 | 2024-10-26 | 2026-03-09 | |
| A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma Dara SC, Dara IV - Multiple Myeloma | Phase 3 | Completed | Janssen Research & Development, LLC | 522 | 2017-10-27 | 2025-04-29 |
| A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma DARA SC - Multiple Myeloma | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 6 | 2017-08-10 | 2023-04-14 |
Multiple Myeloma (2) · Immunoglobulin Light-chain Amyloidosis (1)
Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · Peking University People's Hospital (1)
Japan (2) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Czechia (1) · France (1) · Greece (1) · Israel (1) · Italy (1) · Poland (1) · Russia (1) · South Korea (1) · Spain (1) · Sweden (1)
PMID 37022569, PMID 32213342, PMID 32852632, PMID 32915384, PMID 33599794, PMID 35354247, PMID 39971605
2017 (1)